Engineered brain parasites could treat cognitive disorders
Researchers have discovered a way of using engineered brain parasites to deliver treatments for neurological conditions across the blood-brain-barrier.
The study – led by the University of Glasgow in collaboration with Tel Aviv University and an international team of researchers – represents an exciting new field of research.
The team worked with the common brain parasite Toxoplasma gondii, already estimated to be carried by a third of the global population in its dormant state.
Toxoplasma gondii has evolved to travel from the digestive system to the brain where it secretes its proteins into neurons. The study investigated whether the parasite could instead be used to safely deliver key therapeutic proteins that could help treat neurological diseases.
While most neurological conditions, including Alzheimer’s Disease, Parkinson’s and Rett Syndrome, have been linked in some way to protein dysfunction, difficulties with delivering therapies across the blood-brain-barrier has so far limited treatment options.
Many more years of research needed
The team first engineered the parasites to deliver the MeCP2 protein, which has already been proposed as a promising therapeutic target for Rett Syndrome, a debilitating neurological disorder caused by mutations in MECP2 gene.
Further experiments confirmed that the engineered parasites indeed deliver the protein to the target cell location in the lab, in brain organoids and in mice models.
The team are now focused on further engineering the parasites such that it dies after delivering the protein, to prevent them from causing harm to cells.
Professor Lilach Sheiner, one of the leading authors of the study from the University of Glasgow’s School of Infection and Immunity, said: “This is a blue-sky project where our collaborative team was thinking out of the box to try to tackle the long-standing medical challenge of finding a way to successfully deliver treatment to the brain for cognitive disorders.”
“The concept is not without challenges, considering the dangers involved with Toxoplasma infection. For our work to become a treatment reality it will require many more years of careful research and development to enhance efficiency and improve safety.”
Read the paper: ‘Engineering a Brain Parasite for Intracellular Delivery of Proteins to the Central Nervous System’ in Nature Microbiology.
Diana Spencer, Senior Digital Content Editor, DDW
